<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?><!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id><journal-id journal-id-type="publisher-id">JKMS</journal-id><journal-title-group><journal-title>Journal of Korean Medical Science</journal-title></journal-title-group><issn pub-type="ppub">1011-8934</issn><issn pub-type="epub">1598-6357</issn><publisher><publisher-name>The Korean Academy of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.3346/jkms.2006.21.4.596</article-id><article-id pub-id-type="pmid">16891799</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Association of <italic>TNFA</italic> Promoter Region Haplotype in Beh&#x000e7;et's Disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Park</surname><given-names>KyungSook</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>NaYoung</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Nam</surname><given-names>JungHyun</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Bang</surname><given-names>Dongsik</given-names></name><xref ref-type="aff" rid="A2">*</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Eun-So</given-names></name><xref ref-type="aff" rid="A3">&#x02020;</xref></contrib></contrib-group><aff id="A1">Department of Biology, Sungshin Women's University, Seoul, Korea.</aff><aff id="A2"><label>*</label>Department of Dermatology, Yonsei University, College of Medicine, Seoul, Korea.</aff><aff id="A3"><label>&#x02020;</label>Department of Dermatology, Ajou University School of Medicine, Suwon, Korea.</aff><author-notes><corresp>Address for correspondence: Kyung Sook Park, M.D. Department of Biology, Sungshin Women's University, 249-1 Dongsun-dong, Sungbuk-gu, Seoul 136-742, Korea. Tel: +82.2-920-7174, Fax: +82.2-920-7174, <email>kspark@sungshin.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2006</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2006</year></pub-date><volume>21</volume><issue>4</issue><fpage>596</fpage><lpage>601</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2005</year></date><date date-type="accepted"><day>25</day><month>1</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 The Korean Academy of Medical Sciences</copyright-statement><copyright-year>2006</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Although the etiology of Beh&#x000e7;et's Disease (BD; MIM 109650) remains to be clearly elucidated, levels of tumor necrosis factor alpha (TNF-&#x003b1;) have been reported to be significantly elevated in BD patients, and TNF-&#x003b1; blockers have been demonstrated to exhibit some degree of therapeutic efficacy for a certain subset of BD sufferers. In this study, we have conducted an analysis of the <italic>TNFA</italic> haplotypes in the promoter response element that affect the binding affinity of specific transcription factors, in order to characterize their association with the clinical features of BD. Six polymorphisms in the promoter region of <italic>TNFA</italic> were genotyped in 254 BD patients and 344 control subjects, via the PCR-RFLP technique. <italic>TNFA -1031*C</italic>, <italic>-863*A</italic> and <italic>-308*G</italic> alleles were associated with an increased risk of BD (<italic>p</italic>=0.030, OR=1.4; <italic>p</italic>=0.008, OR=1.5; <italic>p</italic>=0.010, OR=1.8, respectively). The sole <italic>TNFA</italic> haplotype -1031C-863A-857C-376G-308G-238G, was associated with a 1.6 fold increase in the risk of BD, whereas the <italic>TNFA</italic> haplotype -1031T-863C-857C-376G-308A-238G was associated with a 0.6 decreased risk of BD. The <italic>TNFA -1031*C</italic>, <italic>-863*A</italic>, <italic>-857*C</italic> and <italic>-308*G</italic> alleles were significantly associated with BD. The findings of this study, collectively, indicate that <italic>TNFA</italic> haplotypes in the promoter response elements may exert significant influence on susceptibility to BD.</p></abstract><kwd-group><kwd>Tumor Necrosis Factor-alpha</kwd><kwd>Behcet Syndrome</kwd><kwd>Haplotypes</kwd><kwd>Polymorphisms, Single Nucleotide</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Beh&#x000e7;et's Disease (BD; MIM 109650) is a chronic multisystem inflammatory disorder of unclear etiology, which is characterized by primary features including recurrent oral and genital ulcers as well as skin and ocular lesions. Other minor manifestations of BD include arthritis, large vessel involvement (LVI), and lesions of central nervous system (CNS) and gastrointestinal (GI) tract. The mean age of onset of BD is in the early 30s, and the male-to-female ratio varies with ethnicity (<xref ref-type="bibr" rid="B1">1</xref>). Although the precise pathogenesis of BD remains a matter of some controversy, genetic, immunological, and environmental factors have been suggested to contribute to the development of BD (<xref ref-type="bibr" rid="B2">2</xref>). Several susceptibility variant genetic alleles, including alleles of Th1 cytokine-associated genes, have been recognized for their effects on the clinical symptoms of BD. A recent study of Turkish multicase families identified several BD susceptibility loci, via whole-genome linkage analysis. The loci with the strongest association with BD were detected at positions 6p22-24 and 12p12-13 (<xref ref-type="bibr" rid="B3">3</xref>).</p><p>Tumor necrosis factor alpha (TNF-&#x003b1;) is a multifunctional, pro-inflammatory cytokine, which performs a variety of functions in innate immune response, including activation of macrophages and apoptosis, which appears to be responsible for the recurrent inflammatory reactions encountered in BD patients. The promoter polymorphism of the<italic>TNFA</italic> gene, which is located on chromosome 6p21.3, has been associated with the expression of TNF-&#x003b1;. TNF-&#x003b1; levels tend to be significantly elevated in active BD patients, and increased production of TNF-&#x003b1; have been associated with clinical deterioration (<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>). Several single nucleotide polymorphisms (SNPs) in the <italic>TNFA</italic> promoter region appear to alter transcription efficiency in response to specific external stimuli (<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>). Excessive or insufficient TNF-&#x003b1; production might be responsible for the variable patterns of the pathogenesis of this disease. These SNPs, as well as TNF-&#x003b1; overproduction, have been associated with susceptibility to or with the severity of, both inflammatory diseases and autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease (<xref ref-type="bibr" rid="B9">9</xref>). There is, currently, a large body of evidence from in vitro experiments which suggests that TNF-&#x003b1; is produced at higher levels in both the monocytes and &#x003b3;/&#x003b4; T cells of BD patients in response to lipopolysaccharide treatment than has been observed in control subjects. However, the mechanism underlying this phenomenon remains to be determined (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>). Also, infliximab (monoclonal anti-TNF-&#x003b1; antibody) and etanercept (a dimeric soluble p75 TNF receptor) have demonstrated a high degree of therapeutic efficacy for suffers of BD coupled with uveitis, intestinal ulcers, and orogenital ulcers (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>).</p><p>Researchers have been attempting for several years to determine whether polymorphisms of the <italic>TNFA</italic> promoter region influence the expression of TNF-&#x003b1; in BD or its susceptibility or its severity and clinical features. The results of these allelic and genotypic associations, however, are somewhat contradictory, as the implicated polymorphic sites and allele frequencies appear to vary substantially among ethnic groups (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). Most notably, <italic>-376G&#x0003e;A</italic> and <italic>-308G&#x0003e;A</italic> are either completely absent or quite rare among Asians, including the Koreans and the Japanese (<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>). Therefore, this study was focused specifically on the haplotypic association of <italic>TNFA</italic> promoter response elements with the risks and clinical features of BD.</p></sec><sec sec-type="methods"><title>MATERIALS AND METHODS</title><sec><title>Subjects</title><p>Two hundred fifty-four patients (130 males and 124 females) from 16 to 66 yr of age registered at the Beh&#x000e7;et's Disease Specialty Clinic of Severance Hospital at the Yonsei University College of Medicine and the Ajou University School of Medicine and 344 healthy Korean controls were included in this case-control study. The youngest onset of BD was 3 yr old and the oldest onset was 58 yr old and the mean age of disease onset was 33.2&#x000b1;10.4 yr old. BD was diagnosed according to the clinical criteria of the International Study Group for Beh&#x000e7;et's Disease or the revised criteria of Beh&#x000e7;et's Disease(<xref ref-type="bibr" rid="B18">18</xref>).</p></sec><sec><title>Genotyping of <italic>TNFA</italic></title><p>Genomic DNA was extracted from peripheral blood by using a QIAamp Blood Mini kit (Quiagen, Valencia, CA, U.S.A.). Six SNPs in the promoter region of <italic>TNFA</italic> gene at the position of <italic>-1031 T&#x0003e;C</italic>, <italic>-863 C&#x0003e; A</italic>, <italic>-857 C&#x0003e;T</italic>, <italic>-376 G&#x0003e;A</italic>, <italic>-308 G&#x0003e;A</italic> and <italic>-238 G&#x0003e;A</italic> (according to GenBank accession No. AB088112) were analyzed by using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods. The <italic>-1031 T&#x0003e;C</italic> was amplified with PCR by using primers 5'-ACAAGGCTGACCAAGAGAGAA-3' and 5'-GTCCCCATACTCGACTTTCAT-3'and was digested with the <italic>Bbs</italic>I restriction enzyme (<xref ref-type="bibr" rid="B19">19</xref>). The <italic>-863 C&#x0003e;A</italic> was amplified by using primers 5'-GGCTCTGAGGAATGGGTTAC-3'and 5'-CTACATGGCCCTGTCTTCGTTACG-3' and was digested with the <italic>Tai</italic>I restriction enzyme (<xref ref-type="bibr" rid="B20">20</xref>). The reverse primer contained one mismatched nucleotide sequence (underlined). Genotyping for <italic>-857C&#x0003e;T</italic> was conducted by using the forward primer 5'-AAGTCGAGTATGGGGACCCCCCGTTAA-3'and the reverse primer 5'-CCCCAGTGTGTGGCCATATCTTCTT-3'which made it possible to use the restriction enzyme <italic>Hinc</italic>II (<xref ref-type="bibr" rid="B19">19</xref>). The <italic>G&#x0003e;A</italic> substitution at position <italic>-376</italic> was analyzed by the <italic>Tsp</italic>509I restriction enzyme by using the primers, 5'-CCCCGTTTTCTCTCCCTCAA-3'and 5'-TGTGGTCTGTTTCCTTCTAA-3'(<xref ref-type="bibr" rid="B21">21</xref>). The polymorphic region containing the <italic>Nco</italic>I restriction site at <italic>-308</italic><italic>G&#x0003e;A</italic> was amplified by using primers 5'-AGGCAATAGGTTTTGAGGGCCAT-3'and 5'-TCCTCCCTGCTCCGATTCCG-3'. The <italic>G&#x0003e;A</italic> transition polymorphism at position -238 was examined by PCR using primers 5'-CCCAGAAGACCCCCCTCGGAACC-3'and 5'-ACCTTCTGTCTCGGTTTCTTCTCCATCGC-3'and was digested with the <italic>Hpa</italic>II restriction enzyme (<xref ref-type="bibr" rid="B19">19</xref>). The digested PCR products were electrophoresis on an 8% or 5% polyacrylamide gel and were stained with ethidium bromide to visualize the DNA fragments.</p></sec><sec><title>Statistical analysis</title><p>The Hardy-Weinberg equilibrium and Linkage disequilibrium coefficient Lewontin's D'(&#x000a6;D'&#x000a6;) were performed with the R program v.1.9.1 (<ext-link ext-link-type="uri" xlink:href="http://cran.r-project.org">http://cran.r-project.org</ext-link>). The statistical significance of the difference in <italic>TNFA</italic> allele frequencies between BD patients and controls was examined by the &#x003c7;<sup>2</sup> or Fisher's exact test by using SAS version 8.1 (SAS Institute, Cary, NC, U.S.A.). Haplotypes of each individual were inferred by using the PHASE program, v.2.0.1 (<xref ref-type="bibr" rid="B22">22</xref>). A <italic>p</italic>-value of less than 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 254 Korean BD patients and 344 control subjects were analyzed for six SNPs in the <italic>TNFA</italic> promoter region. The genotype and allele frequencies of the regulatory response element promoter polymorphisms <italic>TNFA</italic> gene of the BD patients and controls are shown in <xref ref-type="table" rid="T1">Table 1</xref>. Distributions of the genotypes of both groups agree with those predicted under the conditions of Hardy-Weinberg equilibrium. The <italic>TNFA -376G&#x0003e;A</italic> was not polymorphic in the Korean population. The <italic>TNFA -1031*C</italic>, <italic>-863*A</italic> and <italic>-308*G</italic> alleles are shown to be significantly associated with BD (<italic>p</italic>=0.030, odds ratio [OR]=1.4; <italic>p</italic>=0.008, OR=1.5; <italic>p</italic>=0.010, OR=1.8, respectively). They were significantly higher in the BD patients suffering from major symptoms (OR=1.4-1.9) and arthritis(OR=1.4-2.9) than in the controls (<xref ref-type="table" rid="T2">Table 2</xref>). There was no association between the presence of minor <italic>-238*A</italic> allele and the symptoms of BD except for BD with GI lesions.</p><p>The age at which an individual first manifests major symptoms of the BD appears to be genetically influenced. The <italic>TNFA</italic> promoter SNPs influenced the age onset (before 20 yr) in BD. The <italic>TNFA -1031*C</italic>, <italic>-863*A</italic> and <italic>-857*C</italic> alleles were shown to have a significantly higher association among the BD patients whose onset age is younger than 20 yr old when compared with those whose onset age is after 20 yr old (<italic>p</italic>=0.03-0.04, OR=1.6-2.5). Significant differences between BD and controls were observed in the distribution of <italic>TNFA -1031*C</italic>, <italic>-863*A</italic> and <italic>-857*C</italic> did show significantly higher ORs in the early onset age group than the later onset age group (OR=1.6-2.5) (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><p><italic>TNFA</italic> promoter polymorphisms showed linkage disequilibrium in the Korean population (<xref ref-type="table" rid="T3">Table 3</xref>). The <italic>TNFA-1031*T</italic> was strong associated with <italic>-863*C</italic> (<italic>p</italic>&#x0003c;0.0001) and <italic>-857*C</italic> (<italic>p</italic>&#x0003c;0.0001). The <italic>-863*C</italic> was in linkage disequilibrium with the <italic>-857*C</italic> (<italic>p</italic>=0.0003). Among 22 estimated haplotypes, the most common haplotype, <italic>TNFA -1031T-863C-857C-376G-308G-238G</italic> (55%) and six common <italic>TNFA</italic> haplotypes were observed in the Korean population. The overall haplotype distributions were found to be significantly different between the BD patients and the controls by the permutation test (<italic>p</italic>=0.02). The <italic>TNFA -1031C-863A-857C-376G-308G-238G</italic> haplotype containing the three alleles <italic>TNFA -1031*C</italic>, <italic>-863*A</italic> and <italic>-308*G</italic> was found to be significantly associated with BD. Conversely, the <italic>TNFA -1031T-863C-857C-376G-308A-238G</italic> which did not have these alleleic polymorphisms was protective against BD (<xref ref-type="table" rid="T4">Table 4</xref>).</p><p>The patients were characterized by clinical features whose major/minor symptoms were oral, genital ulcers, skin, ocular lesions, arthritis, and LVI. The CNS and GI lesions are rare. We investigated the clinical features of the <italic>TNFA</italic> haplotypepositive individuals in terms of the frequency of the haplotype, <italic>TNFA -1031C-863A-857C-376G-308G-238G</italic>, which contains the three alleles <italic>-1031*C</italic>, <italic>-863*A</italic> and <italic>-308*G</italic>. Being compared with the controls, it was significantly over-represented among patients (OR=1.6-3.0) who suffered from oral and genital ulcers, skin and ocular lesions, arthritis and CNS but not among those who suffered from LVI or GI lesions. On the other hand, the haplotype <italic>TNFA -1031T-863C-857C-376G-308A-238G</italic> which does not carry those alleles were shown to significantly reduce the risk of BD than in controls (<italic>p</italic>=0.029-0.013, OR=0.4-0.6) (<xref ref-type="table" rid="T4">Table 4</xref>). Frequencies of <italic>TNFA -1031T-863C-857T-376G-308G-238G</italic> and <italic>TNFA -1031C-863C-857C-376G-308G-238A</italic> haplotypes in the patients with CNS or GI lesions significantly differed from those in the controls, but the number of patients was too small for a statistical analysis (<xref ref-type="table" rid="T4">Table 4</xref>).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Both clinical and polymorphism-focused studies have uncovered evidence suggesting that TNF-&#x003b1; functions as a mediator in the initiation and propagation of BD. Polymorphisms of the <italic>TNFA</italic> promoter region have been associated with BD in several ethnic groups, but it remains somewhat uncertain as to whether this is the results of the existence of susceptibility sites, or to the level of TNF-&#x003b1; expression. In this study, a significant difference was observed between BD patients and controls with regard to the polymorphisms of the regulatory response promoter region of the <italic>TNFA</italic> gene. The alleles, <italic>TNFA -1031*C</italic>, <italic>-863*A</italic> and <italic>-308*G</italic> were closely associated with BD, but <italic>TNFA -376G&#x0003e;A</italic> and <italic>-238G&#x0003e;A</italic> were not significantly associated among Korean sufferers of BD. These results are consistent with findings of studies employing different ethnic groups. The <italic>TNFA -1031*C</italic> allele was strongly association with BD in Caucasian patients, in a previous study conducted in the United Kingdom (<xref ref-type="bibr" rid="B23">23</xref>). The other previous studies involving Turkish and Caucasian patients, the <italic>TNFA -376G&#x0003e;A</italic>, <italic>-308G&#x0003e;A</italic> and <italic>-238G&#x0003e;A</italic> alleles were not significantly associated with BD (<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B25">25</xref>). In studies of haplotypes of the <italic>TNFA</italic> promoter, the <italic>TNFA -1031C-863A-857C-376G-308G-238G</italic> haplotype, which harbors the <italic>-1031*C</italic>, <italic>-863*A</italic> and <italic>-308*G</italic> alleles, was significantly associated with BD. Conversely, the <italic>TNFA -1031T-863C-857C-376G-308A-238G</italic> haplotype, which does not harbor the aforementioned allelic polymorphisms, was associated with a reduced susceptibility to BD. The same results were reported in Caucasian BD patients in the United Kingdom (<xref ref-type="bibr" rid="B23">23</xref>). We compared the risk of BD between the early onset age group and the later onset of group, with regard to the <italic>TNFA</italic> alleles. The <italic>-1031*C</italic>, <italic>-863*A</italic> and <italic>-857*C</italic> alleles were detected with a significantly greater frequency in the former than in the latter.</p><p>Inflammation in cases of BD is believed to be mediated by cytokines derived from T-helper type 1 lymphocytes, including TNF-&#x003b1;(<xref ref-type="bibr" rid="B26">26</xref>). It appears that disease activity can be significantly associated with the secretion of pro-inflammatory mediators, as the result of the direct activation of circulating monocytes. The pro-inflammatory cytokine, TNF-&#x003b1; , triggers a signaling cascade, converging on the activation of the NF-&#x003ba;B transcription factor, which is also involved in a variety of features of immune response, which in turn constitutes the basis for a host of physiological and pathological processes. The TNF-&#x003b1;/NF-&#x003ba;B pathway also appears to be relevant to human diseases (<xref ref-type="bibr" rid="B27">27</xref>). The enhanced/silenced expression of pro-inflammatory cytokines indicates the presence of a defect in the normal regulatory mechanisms, and this may have a genetic basis. Much of the control of gene expression appears to involve transcription factors (trans-acting) bound to proximal promoter regulatory response sequences (cis-acting). Gene expression is mediated by several sets of cis-acting regulatory regions, including the core or proximal promoter region, and the response elements. The response elements modulate transcription in response to specific external stimuli, including heat shock 70 or interferon-gamma. The response elements are normally located a short distance upstream of the promoter elements. Allele-specific elements may bind the transcriptional factors, OCT-1 and NF-&#x003ba;B, in the <italic>-1031T&#x0003e;C</italic>, <italic>-863C&#x0003e;A</italic> and <italic>-857C&#x0003e;T</italic> of the <italic>TNFA</italic> regulatory response promoter region, which are thought to be involved in a variety of the immune response functions. Although the roles of the allele-dependent binding elements of <italic>TNFA -1031</italic>, <italic>-863</italic> and <italic>-857</italic> SNPs have yet to be precisely delineated, the susceptible sites associated with the development of BD are in the <italic>-1031T&#x0003e;C</italic>, <italic>-863C&#x0003e;A</italic> and <italic>-857C&#x0003e;T</italic> SNPs of the regulatory response promoter region, and not in <italic>-376G&#x0003e;A</italic>, <italic>-308G&#x0003e;A</italic> or <italic>-238G&#x0003e;A</italic> (<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B28">28</xref>-<xref ref-type="bibr" rid="B30">30</xref>). These SNPs also evidenced no relationship with the degree of severity of the clinical features of BD (<xref ref-type="bibr" rid="B15">15</xref>).</p><p>The pro-inflammatory cytokines, TNF-&#x003b1; and mannosebinding lectin (MBL), are potent inducers of inflammation. Elevated levels of these cytokines are frequently associated with the activation of macrophages, thereby influencing the severity of inflammatory responses. Both of these pro-inflammatory cytokines induce local inflammatory responses, and also exert systemic effects. The over-expression of these cytokines may be responsible for the pathogenesis of recurrent BD. It has been reported previously that the <italic>MBL2 HYPA</italic> haplotype, which induces an elevate expression of MBL, was related to susceptibility to BD, and also to the early onset of disease (<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>). TNF-&#x003b1; production tended to be elevated in carriers of the <italic>TNFA -1031*C</italic>, <italic>-863*A</italic> or <italic>-857*T</italic> alleles, who also suffered from severe periodontitis (<xref ref-type="bibr" rid="B19">19</xref>). The frequency with which individuals were determined to harbor both the <italic>TNFA -1031C-863A-857C-376G-308G</italic>and <italic>MBL2 HY--</italic> (<italic>-550*G</italic>, <italic>-221*G</italic>) haplotypes was significantly higher in the BD patient group than among the controls (<italic>p</italic>=0.004). The elevated production of TNF-&#x003b1; and MBL2 haplotypes might serve to accelerate recurrent inflammation, or may play a critical pathogenic role in initiating immune responses, which might also result in the development of BD. A host of genes appear to be related to BD susceptibility, and the <italic>TNFA</italic> promoter haplotypes appear to be fairly important markers with regard to their association with BD.</p><p>In conclusion, the findings of this study indicate that the <italic>TNFA -1031C-863A-857C-308G</italic> haplotype can be confidently associated with the development of BD as well as early age of onset. This haplotype was also determined to be responsible for the enhanced inflammatory reactions seen in cases of BD involving primary symptoms.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p>This study was supported by a grant from <funding-source>Sungshin Women's University</funding-source> in 2004 (<award-id>2004-1-31-007/1</award-id>).</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>DS</given-names></name><name><surname>Oh</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Lee</surname><given-names>SN</given-names></name></person-group><article-title>Influence of sex on patients with Behcet's disease in Korea</article-title><source>J Korean Med Sci</source><year>2003</year><volume>18</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">12692421</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zierhut</surname><given-names>M</given-names></name><name><surname>Mizuki</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Inoko</surname><given-names>H</given-names></name><name><surname>Gul</surname><given-names>A</given-names></name><name><surname>Onoe</surname><given-names>K</given-names></name><name><surname>Isogai</surname><given-names>E</given-names></name></person-group><article-title>Immunology and functional genomics of Behcet's disease</article-title><source>Cell Mol Life Sci</source><year>2003</year><volume>60</volume><fpage>1903</fpage><lpage>1922</lpage><pub-id pub-id-type="pmid">14523551</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karasneh</surname><given-names>J</given-names></name><name><surname>Gul</surname><given-names>A</given-names></name><name><surname>Ollier</surname><given-names>WE</given-names></name><name><surname>Silman</surname><given-names>AJ</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name></person-group><article-title>Whole-genome screening for susceptibility genes in multicase families with Behcet's disease</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>1836</fpage><lpage>1842</lpage><pub-id pub-id-type="pmid">15934084</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oztas</surname><given-names>MO</given-names></name><name><surname>Onder</surname><given-names>M</given-names></name><name><surname>Gurer</surname><given-names>MA</given-names></name><name><surname>Bukan</surname><given-names>N</given-names></name><name><surname>Sancak</surname><given-names>B</given-names></name></person-group><article-title>Serum interleukin 18 and tumor necrosis factor-alpha levels are increased in Behcet's disease</article-title><source>Clin Exp Dermatol</source><year>2005</year><volume>30</volume><fpage>61</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15663506</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayinalp</surname><given-names>N</given-names></name><name><surname>Ozcebe</surname><given-names>OI</given-names></name><name><surname>Ozdemir</surname><given-names>O</given-names></name><name><surname>Haznedaroglu</surname><given-names>IC</given-names></name><name><surname>Dundar</surname><given-names>S</given-names></name><name><surname>Kirazli</surname><given-names>S</given-names></name></person-group><article-title>Cytokines in Behcet's disease</article-title><source>J Rheumatol</source><year>1996</year><volume>23</volume><fpage>321</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">8882039</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>T</given-names></name><name><surname>Seki</surname><given-names>N</given-names></name><name><surname>Kamizono</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>A</given-names></name><name><surname>Kimura</surname><given-names>A</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Itoh</surname><given-names>K</given-names></name></person-group><article-title>Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese</article-title><source>Tissue Antigens</source><year>1998</year><volume>51</volume><fpage>605</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">9694352</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Symons</surname><given-names>JA</given-names></name><name><surname>McDowell</surname><given-names>TL</given-names></name><name><surname>McDevitt</surname><given-names>HO</given-names></name><name><surname>Duff</surname><given-names>GW</given-names></name></person-group><article-title>Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>3195</fpage><lpage>3199</lpage><pub-id pub-id-type="pmid">9096369</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroeger</surname><given-names>KM</given-names></name><name><surname>Carville</surname><given-names>KS</given-names></name><name><surname>Abraham</surname><given-names>LJ</given-names></name></person-group><article-title>The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription</article-title><source>Mol Immunol</source><year>1997</year><volume>34</volume><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">9293772</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negoro</surname><given-names>K</given-names></name><name><surname>Kinouchi</surname><given-names>Y</given-names></name><name><surname>Hiwatashi</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Satoh</surname><given-names>J</given-names></name><name><surname>Shimosegawa</surname><given-names>T</given-names></name><name><surname>Toyota</surname><given-names>T</given-names></name></person-group><article-title>Crohn's disease is associated with novel polymorphisms in the 5'-flanking region of the tumor necrosis factor gene</article-title><source>Gastroenterology</source><year>1999</year><volume>117</volume><fpage>1062</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">10535868</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mege</surname><given-names>JL</given-names></name><name><surname>Dilsen</surname><given-names>N</given-names></name><name><surname>Sanguedolce</surname><given-names>V</given-names></name><name><surname>Gul</surname><given-names>A</given-names></name><name><surname>Bongrand</surname><given-names>P</given-names></name><name><surname>Roux</surname><given-names>H</given-names></name><name><surname>Ocal</surname><given-names>L</given-names></name><name><surname>Inanc</surname><given-names>M</given-names></name><name><surname>Capo</surname><given-names>C</given-names></name></person-group><article-title>Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects</article-title><source>J Rheumatol</source><year>1993</year><volume>20</volume><fpage>1544</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">8164212</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>N</given-names></name><name><surname>Kaneoka</surname><given-names>H</given-names></name><name><surname>Kaneko</surname><given-names>S</given-names></name><name><surname>Takeno</surname><given-names>M</given-names></name><name><surname>Oneda</surname><given-names>K</given-names></name><name><surname>Koizumi</surname><given-names>H</given-names></name><name><surname>Kogure</surname><given-names>M</given-names></name><name><surname>Inaba</surname><given-names>G</given-names></name><name><surname>Sakane</surname><given-names>T</given-names></name></person-group><article-title>Role of &#x003b3;/&#x003b4; T lymphocytes in the development of Behcet's disease</article-title><source>Clin Exp Immunol</source><year>1997</year><volume>107</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">9030859</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfikakis</surname><given-names>PP</given-names></name><name><surname>Theodossiadis</surname><given-names>PG</given-names></name><name><surname>Katsiari</surname><given-names>CG</given-names></name><name><surname>Kaklamanis</surname><given-names>P</given-names></name><name><surname>Markomichelakis</surname><given-names>NN</given-names></name></person-group><article-title>Effect of infliximab on sight-threatening panuveitis in Behcet's disease</article-title><source>Lancet</source><year>2001</year><volume>358</volume><fpage>295</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">11498218</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melikoglu</surname><given-names>M</given-names></name><name><surname>Fresko</surname><given-names>I</given-names></name><name><surname>Mat</surname><given-names>C</given-names></name><name><surname>Ozyazgan</surname><given-names>Y</given-names></name><name><surname>Gogus</surname><given-names>F</given-names></name><name><surname>Yurdakul</surname><given-names>S</given-names></name><name><surname>Hamuryudan</surname><given-names>V</given-names></name><name><surname>Yazici</surname><given-names>H</given-names></name></person-group><article-title>Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study</article-title><source>J Rheumatol</source><year>2005</year><volume>32</volume><fpage>98</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">15630733</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>RD</given-names></name></person-group><article-title>Polymorphism of the human TNF-alpha promoter; random variation or functional diversity?</article-title><source>Mol Immunol</source><year>1999</year><volume>36</volume><fpage>1017</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">10698305</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ates</surname><given-names>AK</given-names></name><name><surname>Kinikli</surname><given-names>G</given-names></name><name><surname>Duzgun</surname><given-names>N</given-names></name><name><surname>Duman</surname><given-names>M</given-names></name></person-group><article-title>Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behcet's disease</article-title><source>Rheumatol Int</source><year>2006</year><volume>26</volume><fpage>348</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">15875188</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XT</given-names></name><name><surname>Ohtsuka</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Muroi</surname><given-names>M</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>J</given-names></name><name><surname>Munakata</surname><given-names>M</given-names></name></person-group><article-title>Antithetical effect of tumor necrosis factor-alpha gene polymorphism on coal workers' pneumoconiosis (CWP)</article-title><source>Am J Ind Med</source><year>2005</year><volume>48</volume><fpage>24</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">15940715</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>EB</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>MH</given-names></name><name><surname>Song</surname><given-names>YW</given-names></name></person-group><article-title>TNF and TNF receptor polymorphisms in Korean Behcet's disease patients</article-title><source>Hum Immunol</source><year>2003</year><volume>64</volume><fpage>614</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">12770792</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><collab>International Study Group for Behcet's Disease</collab><article-title>Criteria for diagnosis of Behcet's disease</article-title><source>Lancet</source><year>1990</year><volume>335</volume><fpage>1078</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">1970380</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soga</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>F</given-names></name><name><surname>Ohyama</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Takashiba</surname><given-names>S</given-names></name><name><surname>Murayama</surname><given-names>Y</given-names></name></person-group><article-title>Tumor necrosis factor-alpha gene (TNF-alpha) -1031/-863, -857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese</article-title><source>J Clin Periodontol</source><year>2002</year><volume>30</volume><fpage>524</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">12795791</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skoog</surname><given-names>T</given-names></name><name><surname>van't Hooft</surname><given-names>FM</given-names></name><name><surname>Kallin</surname><given-names>B</given-names></name><name><surname>Jovinge</surname><given-names>S</given-names></name><name><surname>Boquist</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name></person-group><article-title>A common functional polymorphism (C-&#x0003e;A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha</article-title><source>Hum Mol Genet</source><year>1999</year><volume>8</volume><fpage>1443</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">10400991</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moukoko</surname><given-names>CE</given-names></name><name><surname>El Wali</surname><given-names>N</given-names></name><name><surname>Saeed</surname><given-names>OK</given-names></name><name><surname>Mohamed-Ali</surname><given-names>Q</given-names></name><name><surname>Gaudart</surname><given-names>J</given-names></name><name><surname>Dessein</surname><given-names>AJ</given-names></name><name><surname>Chevillard</surname><given-names>C</given-names></name></person-group><article-title>No evidence for a major effect of tumor necrosis factor alpha gene polymorphisms in periportal fibrosis caused by Schistosoma mansoni infection</article-title><source>Infect Immun</source><year>2003</year><volume>71</volume><fpage>5456</fpage><lpage>5460</lpage><pub-id pub-id-type="pmid">14500462</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>NJ</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name></person-group><article-title>A new statistical method for haplotype reconstruction from population data</article-title><source>Am J Hum Genet</source><year>2001</year><volume>68</volume><fpage>978</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">11254454</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Wallace</surname><given-names>GR</given-names></name><name><surname>James</surname><given-names>T</given-names></name><name><surname>Neville</surname><given-names>M</given-names></name><name><surname>Bunce</surname><given-names>M</given-names></name><name><surname>Mulcahy-Hawes</surname><given-names>K</given-names></name><name><surname>Armuzzi</surname><given-names>A</given-names></name><name><surname>Crawshaw</surname><given-names>J</given-names></name><name><surname>Fortune</surname><given-names>F</given-names></name><name><surname>Walton</surname><given-names>R</given-names></name><name><surname>Stanford</surname><given-names>MR</given-names></name><name><surname>Welsh</surname><given-names>KI</given-names></name><name><surname>Marshall</surname><given-names>SE</given-names></name><name><surname>Jewell</surname><given-names>DP</given-names></name></person-group><article-title>Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms?</article-title><source>Arthritis Rheum</source><year>2003</year><volume>48</volume><fpage>807</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">12632436</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duymaz-Tozkir</surname><given-names>J</given-names></name><name><surname>Gul</surname><given-names>A</given-names></name><name><surname>Uyar</surname><given-names>FA</given-names></name><name><surname>Ozbek</surname><given-names>U</given-names></name><name><surname>Saruhan-Direskeneli</surname><given-names>G</given-names></name></person-group><article-title>Tumour necrosis factor-alpha gene promoter region -308 and -376 G--&#x0003e;A polymorphisms in Behcet's disease</article-title><source>Clin Exp Rheumatol</source><year>2003</year><volume>21</volume><issue>Suppl 30</issue><fpage>15</fpage><lpage>18</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Oz</surname><given-names>D</given-names></name><name><surname>Karsli</surname><given-names>F</given-names></name><name><surname>Atalay</surname><given-names>A</given-names></name><name><surname>Sahin</surname><given-names>S</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Bang</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name></person-group><article-title>TNF-alpha gene polymorphisms in Behcet's disease</article-title><source>Proceedings of the 9th international conference on Behcet's disease</source><year>2000</year><publisher-loc>Seoul</publisher-loc><publisher-name>Design Mecca Publishing</publisher-name><fpage>161</fpage><lpage>165</lpage></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gul</surname><given-names>A</given-names></name></person-group><article-title>Behcet's disease: an update on the pathogenesis</article-title><source>Clin Exp Rheumatol</source><year>2001</year><volume>19</volume><issue>Suppl 24</issue><fpage>6</fpage><lpage>12</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouwmeester</surname><given-names>T</given-names></name><name><surname>Bauch</surname><given-names>A</given-names></name><name><surname>Ruffner</surname><given-names>H</given-names></name><name><surname>Angrand</surname><given-names>PO</given-names></name><name><surname>Bergamini</surname><given-names>G</given-names></name><name><surname>Croughton</surname><given-names>K</given-names></name><name><surname>Cruciat</surname><given-names>C</given-names></name><name><surname>Eberhard</surname><given-names>D</given-names></name><name><surname>Gagneur</surname><given-names>J</given-names></name><name><surname>Ghidelli</surname><given-names>S</given-names></name><name><surname>Hopf</surname><given-names>C</given-names></name><name><surname>Huhse</surname><given-names>B</given-names></name><name><surname>Mangano</surname><given-names>R</given-names></name><name><surname>Michon</surname><given-names>AM</given-names></name><name><surname>Schirle</surname><given-names>M</given-names></name><name><surname>Schlegl</surname><given-names>J</given-names></name><name><surname>Schwab</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>MA</given-names></name><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Casari</surname><given-names>G</given-names></name><name><surname>Drewes</surname><given-names>G</given-names></name><name><surname>Gavin</surname><given-names>AC</given-names></name><name><surname>Jackson</surname><given-names>DB</given-names></name><name><surname>Joberty</surname><given-names>G</given-names></name><name><surname>Neubauer</surname><given-names>G</given-names></name><name><surname>Rick</surname><given-names>J</given-names></name><name><surname>Kuster</surname><given-names>B</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name></person-group><article-title>A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway</article-title><source>Nat Cell Biol</source><year>2004</year><volume>6</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">14743216</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udalova</surname><given-names>IA</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Denys</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Ackerman</surname><given-names>H</given-names></name><name><surname>Foxwell</surname><given-names>B</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name></person-group><article-title>Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region</article-title><source>Mol Cell Biol</source><year>2000</year><volume>20</volume><fpage>9113</fpage><lpage>9119</lpage><pub-id pub-id-type="pmid">11094063</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Heel</surname><given-names>DA</given-names></name><name><surname>Udalova</surname><given-names>IA</given-names></name><name><surname>De Silva</surname><given-names>AP</given-names></name><name><surname>McGovern</surname><given-names>DP</given-names></name><name><surname>Kinouchi</surname><given-names>Y</given-names></name><name><surname>Hull</surname><given-names>J</given-names></name><name><surname>Lench</surname><given-names>NJ</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Carey</surname><given-names>AH</given-names></name><name><surname>Jewell</surname><given-names>DP</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name></person-group><article-title>Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF (-kappa) B transcription factors</article-title><source>Hum Mol Genet</source><year>2002</year><volume>11</volume><fpage>1281</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">12019209</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verity</surname><given-names>DH</given-names></name><name><surname>Wallace</surname><given-names>GR</given-names></name><name><surname>Vaughan</surname><given-names>RW</given-names></name><name><surname>Kondeatis</surname><given-names>E</given-names></name><name><surname>Madanat</surname><given-names>W</given-names></name><name><surname>Zureikat</surname><given-names>H</given-names></name><name><surname>Fayyad</surname><given-names>F</given-names></name><name><surname>Marr</surname><given-names>JE</given-names></name><name><surname>Kanawati</surname><given-names>CA</given-names></name><name><surname>Stanford</surname><given-names>MR</given-names></name></person-group><article-title>HLA and tumour necrosis factor (TNF) polymorphisms in ocular Behcet's disease</article-title><source>Tissue Antigens</source><year>1999</year><volume>54</volume><fpage>264</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">10519363</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Min</surname><given-names>K</given-names></name><name><surname>Nam</surname><given-names>JH</given-names></name><name><surname>Bang</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name></person-group><article-title>Association of HYPA haplotype in the mannose-binding lectin gene-2 with Behcet's disease</article-title><source>Tissue Antigens</source><year>2005</year><volume>65</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15730518</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>HO</given-names></name><name><surname>Garred</surname><given-names>P</given-names></name><name><surname>Thiel</surname><given-names>S</given-names></name><name><surname>Kurtzhals</surname><given-names>JA</given-names></name><name><surname>Lamm</surname><given-names>LU</given-names></name><name><surname>Ryder</surname><given-names>LP</given-names></name><name><surname>Svejgaard</surname><given-names>A</given-names></name></person-group><article-title>Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein</article-title><source>J Immunol</source><year>1995</year><volume>155</volume><fpage>3013</fpage><lpage>3020</lpage><pub-id pub-id-type="pmid">7673719</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><p>Allele frequency of the <italic>TNFA</italic> promoter in BD onset age.</p></caption><graphic xlink:href="jkms-21-596-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Genotype and allele frequencies of the <italic>TNFA</italic> promoter SNPs in BD patients and controls</p></caption><graphic xlink:href="jkms-21-596-i001"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>The allele frequency of <italic>TNFA</italic> for clinical feature of BD patients</p></caption><graphic xlink:href="jkms-21-596-i002"/></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Linkage disequilibria (&#x000a6;D'&#x000a6;) among SNP of <italic>TNFA</italic> in the Korean population (n=344)</p></caption><graphic xlink:href="jkms-21-596-i003"/><table-wrap-foot><fn><p>&#x000a6;D'&#x000a6; value is given above the diagonal; <italic>p</italic> value is given below the diagonal.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Clinical features associated with <italic>TNFA</italic> haplotype</p></caption><graphic xlink:href="jkms-21-596-i004"/></table-wrap></floats-group></article>